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Background. Hepatitis C virus (HCV) direct-acting antiviral therapy is effective among people receiving opioid substitution 
therapy (OST), but studies are limited by small numbers of nongenotype 1 (GT1) patients. The aim of this study was to evaluate the 
treatment completion, adherence, SVR12, and safety of sofosbuvir-based therapies in HCV patients receiving and not receiving OST.
Methods. Ten phase 3 studies of sofosbuvir-based regimens included ION (ledipasvir/sofosbuvir ± ribavirin for 8, 12, or 24 
weeks in GT1), ASTRAL (sofosbuvir/velpatasvir for 12 weeks in GT1-6), and POLARIS (sofosbuvir/velpatasvir and sofosbuvir/
velpatasvir/voxilaprevir in GT1-6). Patients with clinically significant drug use (last 12 months) or noncannabinoids detected at 
screening were ineligible.
Results. Among 4743 patients, 4% (n = 194) were receiving OST (methadone; n = 113; buprenorphine, n = 75; other, n = 6). 
Compared with those not receiving OST (n = 4549), those receiving OST (n = 194) were younger (mean age, 48 vs 54), more often 
male (73% vs 61%), GT3 (38% vs 17%), treatment-naïve (78% vs 65%), and cirrhotic (36% vs 23%). Among those receiving and not 
receiving OST, there was no significant difference in treatment completion (97% vs 99%, P = .06), SVR12 (94% vs 97%, P = .06), 
relapse (0.5% vs 2.1%, P = .19), adverse events (78% vs 77%, P = .79), or serious adverse events (3.6% vs 2.4%, P = .24). There was no 
difference in SVR12 in patients with cirrhosis (99% vs 95%, P = .25) or those with G3 (95% vs 95%, P = .77) in those receiving OST. 
Among patients receiving OST, SVR12 was high among those receiving methadone (95%) and buprenorphine (96%).
Conclusion. Sofosbuvir-based therapies are effective and safe in patients receiving OST.
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People who inject drugs (PWID) are disproportionately affected 
by hepatitis C virus (HCV) infection [1, 2]. Despite increas-
ing liver-related morbidity and mortality among PWID [2, 3], 
some clinicians are reluctant to prescribe direct-acting antiviral 
(DAA) therapy for PWID or people receiving opioid substitu-
tion therapy (OST) based on concerns of poor adherence, lower 
response to therapy, and high rates of reinfection [4]. This is 
inconsistent with international guidelines recommending that 
all people should receive HCV treatment and that PWID should 
be prioritized, given the potential to reduce transmission to 
others [5–8]. Further data on treatment outcomes among 
populations of PWID receiving DAA therapy, including those 
receiving OST, are needed to change HCV health policy and 
clinical practice.
People with a history of injecting drug use include former 
injectors who have ceased injecting and recent PWID [9]. Some 
people with a history of injecting drug use may also be receiv-
ing OST (eg, methadone, buprenorphine) for the management 
of opioid dependence. Interferon-based therapy is effective in 
people with a history of injecting drug use, including those 
with recent injecting drug use and those receiving OST, with 
responses similar to that observed in large clinical studies 
[10–12]. Although data are emerging on outcomes to DAA-
based HCV therapy among PWID receiving OST [13–23], 
most studies are limited by small numbers of HCV nongeno-
type 1 patients. There are also no published studies on the effi-
cacy and safety of sofosbuvir/velpatasvir/voxilaprevir in people 
receiving OST.
Phase 3 studies of sofosbuvir-based therapy (the ION, 
ASTRAL, and POLARIS studies) included the evaluation of 
ledipasvir/sofosbuvir with or without ribavirin, sofosbuvir/
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velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir in patients 
with chronic HCV genotype 1–6 [24–30]. People receiving 
stable OST were eligible for inclusion, but people with clin-
ically relevant illicit drug use within 12 months of screening 
or illicit drugs (excluding cannabinoids) detected by a urine 
drug test at screening were excluded from study participation. 
These clinical trial populations are highly selected and may 
not be representative of recent PWID populations. However, 
studies in these populations contribute to the growing body 
of evidence on interferon-free DAA therapy among people 
receiving OST, particularly people with HCV nongenotype 1 
infection.
The aim of this post hoc analysis of the phase 3 studies of 
sofosbuvir-based therapy was to evaluate the treatment comple-
tion, adherence, SVR12, and safety of sofosbuvir-based therapy 
in patients receiving OST and not receiving OST.
METHODS
Study Participants and Design
From October 2012 to May 2016, participants were enrolled in 
10 multicenter, randomized clinical studies, including ION-1–3 
(ClinicalTrials.gov identifier: NCT01701401, NCT01768286, 
and NCT01851330, respectively [24–26]), ASTRAL-1–3 
(ClinicalTrials.gov: NCT02201940, NCT02220998, and 
NCT02201953, respectively [27, 28]), and POLARIS-1–4 
(ClinicalTrials.gov: NCT02607735, NCT02607800, 
NCT02639338, and NCT02639247 [29, 30]).
In the ION-1–3 studies, a fixed-dose combination tablet of 
ledipasvir/sofosbuvir 90 mg/400 mg was administered for 8, 12, 
or 24 weeks with or without ribavirin in patients with chronic 
HCV genotype 1 infection [24–26]. Twice-daily ribavirin dose 
was given according to body weight (1000 mg daily < 75 kg or 
1200 mg daily ≥ 75 kg). In the ASTRAL-1–3 studies, a fixed-dose 
combination tablet of sofosbuvir/velpatasvir 400 mg/100 mg was 
administered for 12 weeks in patients with chronic HCV geno-
types 1–6 [27, 28]. In the POLARIS studies, a fixed-dose com-
bination tablet of sofosbuvir/velpatasvir 400  mg/100  mg was 
administered for 12 weeks or a fixed-dose combination tablet of 
sofosbuvir/velpatasvir/voxilaprevir 400 mg/100 mg/100 mg was 
administered for 8 or 12 weeks in patients with chronic HCV 
genotypes 1–6 [29, 30].
Participants receiving OST (eg, methadone or buprenor-
phine with and without naloxone) were eligible for inclusion 
(OST determined based on reported concomitant medica-
tions). Patients were excluded from enrollment in these stud-
ies if they had clinically significant drug use within 12 months 
of screening (as assessed by the investigator based on partic-
ipant self-report or medical chart review) or illicit drug use 
(excluding cannabinoids) detected by a urine drug test during 
the screening phase that was not explained by a prescription 
medication. The designs and results of these studies have been 
described previously [24–30].
Study End Points
In this analysis, the end points included treatment comple-
tion, adherence (≥90% of doses), SVR12, safety (adverse events 
[AEs], serious AEs, and hemoglobin level <10 g/dL), and rein-
fection. The analyzed population included all randomized 
patients who received ≥1 dose of study medication. Adherence 
was measured by counting the number of unused tablets in the 
returned bottles to derive the number of administrated tablets. 
In situations where a bottle was not returned, the number of 
tablets administered from that bottle will be assumed to be 
0.  Adherence was calculated by dividing the number of total 
doses administered during therapy (determined by pill counts 
at week 4, 8, 12, 16, and 24 [where applicable] study visits) by 
the total expected number of prescribed doses. SVR12 was 
defined as the absence of quantifiable HCV RNA in serum (<25 
IU/mL or <15 IU/mL), measured by COBAS TaqMan HCV 
Test, v2.0 (Roche Molecular Systems), at 12 weeks after the end 
of study treatment. Participants were monitored for recurrence 
(viral relapse or reinfection) at 4 weeks, 12 weeks (SVR12), and 
24 weeks (SVR24) following the completion of treatment. Deep 
sequencing of the HCV NS5A and NS5B genes was performed 
for all patients at baseline and again for all patients with viro-
logic failure in samples obtained at the first time point of failure 
with an HCV RNA >1000 IU/mL [24–30]. Phylogenetic analy-
ses were used to distinguish viral relapse from reinfection.
Statistical Analysis
Descriptive statistics, including means, frequencies, and per-
centages (with 95% confidence intervals [CIs] for SVR12) were 
used to summarize the data. The proportion of participants 
with treatment completion, ≥90% adherence, SVR12, and AEs 
was compared among people receiving and not receiving OST. 
Comparisons were made using a 2-sided Fisher exact test. All 
P values are 2-sided; a level of .05 was considered statistically 
significant. Statistical analysis was performed using SAS 9.4 
software (SAS Institute Inc., Cary, NC).
RESULTS
Participant Characteristics
Overall, 4743 patients were enrolled and treated in the ION 
(n = 1952; ION-1, n = 865; ION-2, n = 440; ION-3, n = 647), 
ASTRAL (n = 1035; ASTRAL-1, n = 624; ASTRAL-2, n = 134; 
ASTRAL-3, n  =  277), and POLARIS studies (n  =  1756; 
POLARIS-1, n  =  263; POLARIS-2, n  =  941; POLARIS-3, 
n = 333; POLARIS-4, n = 219). Among individuals in all these 
studies, 4% (n = 194) were receiving OST at enrollment.
The clinical characteristics of the study participants are 
shown in Table 1. Among patients receiving OST (n = 194), 27% 
(n = 53) received ledipasvir/sofosbuvir with or without ribavi-
rin (for 8, 12, or 24 weeks), 47% (n = 92) received sofosbuvir/
velpatasvir for 12 weeks, and 25% (n = 49) received sofosbuvir/
velpatasvir/voxilaprevir (for 8 or 12 weeks). Among patients not 
receiving OST (n = 4549), 42% (n = 1899) received ledipasvir/
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sofosbuvir with or without ribavirin (for 8, 12, or 24 weeks), 
36% (n  =  1643) received sofosbuvir/velpatasvir for 12 weeks, 
and 22% (n  =  1007) received sofosbuvir/velpatasvir/voxila-
previr (for 8 or 12 weeks).
Among patients receiving OST (n = 194), 36% (n = 70) had 
cirrhosis, 22% (n = 42) were treatment-experienced, and 38% 
(n = 74) were infected with HCV genotype 3. Among patients 
not receiving OST (n = 4549), 23% (n = 1041) had cirrhosis, 
34% (n = 1568) were treatment-experienced, and 17% (n = 787) 
were infected with HCV genotype 3.
HCV Treatment Completion and Adherence
The proportion of participants completing HCV therapy 
was 97.4% (189/194; 95% CI, 94.1%–99.2%) among partic-
ipants receiving OST, compared with 98.9% (4501/4549; 95% 
CI, 98.6%–99.2%) among those not receiving OST (P =  .064) 
(Table  2). The reasons for treatment discontinuation among 
patients receiving OST (n  =  5) included AEs (n  =  1), loss to 
follow-up (n = 1), consent withdrawal (n = 1), lack of efficacy 
(n = 1), and noncompliance (n = 1). The reasons for treatment 
discontinuation among patients not receiving OST (n  =  48) 
included AEs (n  =  19), loss to follow-up (n  =  10), consent 
withdrawal (n = 6), protocol violation (n = 6), lack of efficacy 
(n = 4), noncompliance (n = 1), and pregnancy (n = 2). Among 
patients receiving OST, the proportion of participants complet-
ing therapy with ledipasvir/sofosbuvir with or without ribavirin 
was 96.2% (51/53), sofosbuvir/velpatasvir was 96.7% (89/92), 
and sofosbuvir/velpatasvir/voxilaprevir was 100% (49/49).
The proportion of participants with ≥90% adherence to ther-
apy was 90.2% (175/194; 95% CI, 85.1%–94.0%) among partic-
ipants receiving OST, compared with 94.3% (4291/4549; 95% 
CI, 93.6%–95.0%) among those not receiving OST (P =  .027) 
(Table 2). Of the 19 patients receiving OST who had ˂90% cal-
culated adherence, 12 patients achieved SVR12 and 7 patients 
failed to achieve SVR12 (3 were lost to follow-up, 1 withdrew 
consent on day 29, 1 had virologic breakthrough and drug lev-
els consistent with nonadherence, 1 discontinued on day 1 due 
to AE, 1 was discontinued by the investigator on day 5 due to 
nonadherence). Among patients receiving OST, the proportion 
of participants with ≥90% adherence with ledipasvir/sofosbuvir 
with or without ribavirin was 88.7% (47/53), sofosbuvir/vel-
patasvir was 89.1% (82/92), and sofosbuvir/velpatasvir/voxila-
previr was 93.9% (46/49).
HCV Treatment Outcomes
The proportion with SVR12 among those receiving OST was 
94.3% (183/194; 95% CI, 90.1%–97.1%) compared with 96.8% 
for those not receiving OST (4405/4549; 95% CI, 96.3%–97.3%; 
P  =  .062) (Table  2). SVR12 by treatment type and duration 
for participants receiving and not receiving OST is shown in 
Table 2.
Among patients receiving OST, the proportion of partic-
ipants with SVR12 with ledipasvir/sofosbuvir with or with-
out ribavirin was 92.5% (49/53), sofosbuvir/velpatasvir was 
94.6% (87/92), and sofosbuvir/velpatasvir/voxilaprevir was 
95.9% (47/49). Further, among patients with HCV genotype 3, 
the response to therapy among patients receiving sofosbuvir/
velpatasvir was 95.8% (46/48) and receiving sofosbuvir/vel-
patasvir/voxilaprevir was 92.3% (24/26).
Among patients receiving OST, the proportion of partici-
pants with SVR12 among people with F0 was 88.1% (37/42), 
with F1 was 91.3% (21/23), with F2 was 97.8% (44/45), with F3 
was 93.3% (28/30), and with F4 was 98.0% (50/51).
Table 1. Baseline Demographic and Clinical Characteristics of Patients 
With Chronic HCV Infection Receiving Sofosbuvir-Based Therapies in the 










Mean (SD) age, y 48 (10.7) 54 (10.4)
Male sex, n (%) 141 (73) 2770 (61)
HCV genotype, n (%)a
 1a 84 (43) 2109 (46)
 1b 12 (6) 816 (18)
 2 14 (7) 409 (9)
 3 74 (38) 787 (17)
 4 10 (5) 269 (6)
 5 0 54 (1)
 6 0 86 (2)
HCV RNA log10 IU/mL, mean (SD) 6.3 (0.7) 6.3 (0.7)
HCV RNA ≥ 800 000 IU/mL, n (%) 142 (73) 3456 (76)
Fibrosis stage
 F0 42 (22) 826 (18)
 F1 23 (12) 410 (9)
 F2 45 (24) 1141 (25)
 F3 30 (16) 721 (16)
 F4 51 (27) 1410 (31)
Treatment-experienced, n (%) 42 (22) 1568 (34)
Therapy
 Ledipasvir/sofosbuvir ± ribavirin 
(8 wk)
8 (4) 423 (9)
 Ledipasvir/sofosbuvir ± ribavirin 
(12 wk)
32 (16) 835 (18)
 Ledipasvir/sofosbuvir ± ribavirin 
(24 wk)
13 (7) 641 (14)
 Sofosbuvir/velpatasvir (12 wk) 92 (47) 1643 (36)
 Sofosbuvir/velpatasvir/voxilaprevir 
(8 wk)
41 (21) 570 (13)
 Sofosbuvir/velpatasvir/voxilaprevir 
(12 wk)
8 (4) 437 (10)
OST, n (%)
 Methadone 113 (58) -
 Buprenorphine 35 (18) -
 Buprenorphine/naloxone 40 (21) -
 Other 6 (3) -
Abbreviations: HCV, hepatitis C virus; OST, opioid substitution therapy.
aNineteen patients were classified as other, unknown, or missing, and all were not receiv-
ing OST at enrollment.
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Among patients receiving OST across treatment regimens, 
there was no difference in SVR12 in those receiving methadone 
and buprenorphine (94.7% vs 96.0%, P = 1.0), patients with and 
without cirrhosis (98.6% vs 91.9%, P = .089), and patients with 
genotype 3 as compared with genotype 1a (94.6% vs 95.2%, 
P = .850).
Safety
The proportions with AEs (78.4%; 95% CI, 71.9%–83.9%; 
vs 77.3%; 95% CI, 76.1%–78.5%; P  =  .790) (Tables 2 and 3) 
and serious AEs (3.6%; 95% CI, 1.5%–7.3%; vs 2.4%; 95% CI, 
2.0%–2.9%; P = .200) (Table 2) were similar among participants 
receiving and not receiving OST. AEs were mostly mild or mod-
erate in severity.
HCV Reinfection
Two patients were found to have reinfection with a different 
genotype than at baseline. Neither subject was receiving OST 
at baseline. One patient enrolled in ASTRAL-3 had genotype 
3a at baseline and received SOF/VEL for 12 weeks. The patient 
achieved SVR4 and was found to have genotype 1a 12 weeks 
after the completion of therapy. Another patient enrolled in 
POLARIS-2 had genotype 1a and received SOF/VEL for 12 
weeks. The patient achieved SVR12 but was found to have gen-
otype 3a 24 weeks after therapy.
DISCUSSION
This post hoc analysis of sofosbuvir-based therapies from 
the ION, ASTRAL, and POLARIS studies demonstrated high 
SVR12 rates among patients receiving OST, including those 
with HCV genotype 3 receiving sofosbuvir/velpatasvir and 
sofosbuvir/velpatasvir/voxilaprevir. Similar treatment comple-
tion, SVR12, and AE rates were observed among patients with 
chronic HCV genotypes 1–6 receiving and not receiving OST, 
although patients not receiving OST had a significantly higher 
proportion with ≥90% adherence. Collectively, these data add 
to the body of evidence supporting the efficacy and safety of 
DAA treatment for HCV among people receiving stable OST, 
consistent with international recommendations [5–8].
Overall, the SVR was 94% among patients receiving OST 
and sofosbuvir-based therapy, with no observed difference in 
response compared with those not receiving OST, which is con-
sistent with previous post hoc analyses of the ION and ASTRAL 
studies [21, 22] and other studies in this population [23]. These 
results are also comparable with a large phase 3 study of peo-
ple receiving stable OST (recent injecting drug use at screen-
ing was permitted) and HCV genotype 1, 4, and 6 infection 
receiving elbasvir/grazoprevir for 12 weeks, where an SVR of 
91% was observed [20]. This study adds to the literature by 
Table 2. Treatment and Safety Outcomes Among Patients With Chronic HCV Infection Receiving Sofosbuvir-Based Therapies in the ION, ASTRAL, and 
POLARIS Phase 3 Clinical Trials, by Receipt of Opioid Substitution Therapy 
Characteristic OST at Enrollment No OST at Enrollment P
Overall, n/N (%)
 Treatment completion 189/194 (97.4) 4501/4549 (98.9) .064
 ≥90% adherence 175/194 (90.2) 4291/4549 (94.3) .027
 SVR12 183/194 (94.3) 4405/4549 (96.8) .062
 Adverse events 152/194 (78.4) 3517/4549 (77.3) .79
 Severe adverse events 7/194 (3.6) 108/4549 (2.4) .24
Ledipasvir/sofosbuvir ± ribavirin
 Treatment completion 51/53 (96.2) 1863/1899 (98.1) .28
 ≥90% adherence 47/53 (88.7) 1791/1899 (94.3) .12
 SVR12 49/53 (92.5) 1839/1899 (96.8) .093
 Adverse events 47/53 (88.7) 1513/1899 (79.7) .12
 Severe adverse events 2/53 (3.8) 50/1899 (2.6) .65
Sofosbuvir/velpatasvir
 Treatment completion 89/92 (96.7) 1634/1643 (99.5) .022
 ≥90% adherence 82/92 (89.1) 1559/1643 (94.9) .029
 SVR12 87/92 (94.6) 1601/1643 (97.4) .099
 Adverse events 68/92 (73.9) 1251/1643 (76.1) .62
 Severe adverse events 4/92 (4.3) 33/1643 (2.0) .13
Sofosbuvir/velpatasvir/voxilaprevir
 Treatment completion, n (%) 49/49 (100.0) 1004/1007 (99.7) 1.00
 ≥90% adherence 46/49 (93.9) 941/1007 (93.4) 1.00
 SVR12 47/49 (95.9) 965/1007 (95.8) 1.00
 Adverse events 37/49 (75.5) 753/1007 (74.8) 1.00
 Severe adverse events 1/49 (2.0) 25/1007 (2.5) 1.00
Abbreviations: HCV, hepatitis C virus; OST, opioid substitution therapy.
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providing further data among patients with cirrhosis and geno-
type 3 infection in people receiving OST, enabling a more pre-
cise estimate of outcomes in this population. Also, this is the 
first study to report outcomes with the combination of sofos-
buvir/velpatasvir/voxilaprevir in patients stable on OST. These 
data are consistent with previous data demonstrating that inter-
feron-based HCV therapy is safe and effective among people 
receiving OST [10–12, 31–33]. Collectively, these data support 
DAA therapy for patients stable on OST.
Treatment completion was high among people receiving OST 
(97%), with no difference between those not receiving OST, con-
sistent with other studies of interferon-free [21, 22] and inter-
feron-based therapy [10–12, 31, 32]. Adherence to therapy was 
significantly lower in people receiving OST as compared with 
those not receiving OST (90% vs 94%), although it is uncertain 
whether this would be clinically significant. In a meta-analy-
sis of interferon-based studies among PWID, engagement in 
addiction treatment was associated with higher treatment com-
pletion [12]. Previous studies have demonstrated that the colo-
cation of HCV services and drug treatment can be successfully 
integrated [34], with the colocation of HCV care in OST clinics 
welcomed by the large majority of participants and providers 
[35]. Further efforts are needed to expand the integration of 
HCV DAA therapy in drug and alcohol clinics and community 
health clinics that also provide OST. Also, improved education 
and training of practitioners working in drug treatment clinics 
about HCV testing, liver disease assessment, and HCV treat-
ment are required to further develop competency and expand 
HCV treatment access for people receiving OST.
It is notable that there were no cases of HCV reinfection 
following DAA therapy among people receiving OST in the 
ION, ASTRAL, and POLARIS studies. Previous studies have 
demonstrated reinfection rates ranging from 1% to 5% per 100 
person-years following successful interferon-based [10, 36–38] 
and DAA therapy [20] among people with a history of inject-
ing drug use or those receiving OST. However, the sample size 
and duration of follow-up in this study are limited, and the 
included population is likely at lower risk of reinfection, given 
that they were not using illicit drugs at the time of treatment 
initiation. Further long-term studies of HCV reinfection among 
people receiving OST and recent PWID are required to more 
fully characterize the risk of HCV reinfection and associated 
risk factors.
This study has a number of limitations. People with active 
drug use at baseline were excluded from participating in the 
ION, ASTRAL, and POLARIS studies, and as such, enrolled 
participants represented a selected population likely to be 
engaged in care. Therefore, these findings may not be generaliz-
able to other PWID populations (particularly those not receiv-
ing stable OST or recent PWID). Further, this was also a post 
hoc analysis, which was not defined prior to the initiation of 
these studies. Also, the data with respect to adherence must be 
interpreted with caution. Adherence in these studies was meas-
ured by counting the number of pills in returned pill bottles. In 
instances where participants did not return their pill bottles, a 
conservative measure of adherence was used and adherence for 
that period was assumed to be 0%. Given limited data on inter-
feron-free treatment outcomes among people receiving OST 
(particularly people with cirrhosis and HCV genotype 3), these 
data still provide important guidance for HCV management in 
these populations.
In conclusion, these data demonstrate that sofosbuvir-based 
therapy is effective and well tolerated among patients receiv-
ing OST. Although this study provides important data to add 
to the literature on HCV therapy in people receiving OST, fur-
ther data are still needed on DAA therapy among people with 
recent or ongoing injecting drug use. Ongoing clinical trials 
evaluating interferon-free therapy among PWID with recent 
drug use (SIMPLIFY, NCT02336139; HERO, NCT02824640) 
and PWID with recent drug use and/or those receiving OST 
(D3FEAT, NCT02498015) will hopefully provide further data 
in this regard. Global HCV elimination efforts will require the 
inclusion of PWID as a key priority population, and strategies 
are needed to enhance HCV care in this important group.
Table 3. Adverse Events Among Patients With Chronic HCV Infection Receiving Sofosbuvir-Based Therapies in the ION, ASTRAL, and POLARIS Phase 3 
Clinical Studies, by Receipt of Opioid Substitution Therapy






















Adverse events in >10%
 Headache 12 (22.6) 20 (21.7) 8 (16.3) 443 (23.3) 450 (27.4) 269 (26.7)
 Fatigue 19 (35.8) 18 (19.6) 11 (22.4) 556 (29.3) 364 (22.2) 222 (22.0)
 Nausea 12 (22.6) 14 (15.2) 12 (24.5) 253 (13.3) 184 (11.2) 150 (14.9)
 Diarrhea 4 (7.5) 7 (7.6) 5 (10.2) 151 (8.0) 110 (6.7) 183 (18.2)
 Insomnia 5 (9.4) 5 (5.4) 3 (6.1) 232 (12.2) 112 (6.8) 59 (5.9)
 Vomiting 4 (7.5) 6 (6.5) 6 (12.2) 60 (3.2) 42 (2.6) 24 (2.4)
Abbreviations: HCV, hepatitis C virus; OST, opioid substitution therapy.
6 • OFID • Grebely et al
Acknowledgments
Disclaimers. The Kirby Institute is funded by the Australian 
Government Department of Health and Ageing. The views expressed in 
this publication do not necessarily represent the position of the Australian 
Government. Jason Grebely is supported by a National Health and Medical 
Research Council Career Development Fellowship. Gregory Dore is sup-
ported through National Health and Medical Research Council of Australia 
Practitioner Fellowship.
Financial support. This work was supported by Gilead Sciences.
Potential conflicts of interest. Jason Grebely is a consultant/advisor 
and has received research grants from AbbVie, Bristol-Myers Squibb, 
Cepheid, Gilead Sciences, Merck, and Merck Sharp & Dohme. Stefan 
Zeuzem is a consultant for AbbVie, Bristol-Myers Squibb, Gilead Sciences, 
Intercept, Janssen, Merck, and Merck Sharp & Dohme. Gregory Dore 
is a consultant/advisor to and has received research grants from Abbvie, 
Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck, 
Roche, GlaxoSmithKline, and Abbott Diagnostics. Liyun Ni, Joe Llewellyn, 
Heshaam M.  Mir, Nika Sajed, Luisa M.  Stamm, Robert H.  Hyland, John 
McNally, and Diana M.  Brainard are employees of Gilead Sciences. All 
authors have submitted the ICMJE Form for Disclosure of Potential 
Conflicts of Interest. Conflicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug 
use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV 
in people who inject drugs: a multistage systematic review. Lancet Glob Health 
2017; 5:e1192–207.
2. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV 
infection. Nat Rev Gastroenterol Hepatol 2013; 10:553–62.
3. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin 
Liver Dis 2011; 31:331–9.
4. Asher AK, Portillo CJ, Cooper BA, et  al. Clinicians’ views of hepatitis C virus 
treatment candidacy with direct-acting antiviral regimens for people who inject 
drugs. Subst Use Misuse 2016; 51:1218–23.
5. EASL. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017; 
66:153–94.
6. AASLD/IDSA. HCV Guidance: Recommendations for Testing, Managing, and 
Treating Hepatitis C. Available at: https://www.hcvguidelines.org/. Accessed 18 
March 2017.
7. Grebely J, Robaeys G, Bruggmann P, et  al; International Network for Hepatitis 
in Substance Users. Recommendations for the management of hepatitis C virus 
infection among people who inject drugs. Int J Drug Policy 2015; 26:1028–38.
8. WHO. Guidelines for the Screening Care and Treatment of Persons With Chronic 
Hepatitis C Infection. 2016.WHO. http://www.who.int/hepatitis/publications/
hepatitis-c-guidelines-2016/en/. Accessed 13 January 2018.
9. Larney S, Grebely J, Hickman M, et al. Defining populations and injecting param-
eters among people who inject drugs: implications for the assessment of hepatitis 
C treatment programs. Int J Drug Policy 2015; 26:950–7.
10. Aspinall EJ, Corson S, Doyle JS, et  al. Treatment of hepatitis C virus infec-
tion among people who are actively injecting drugs: a systematic review and 
meta-analysis. Clin Infect Dis 2013; 57(Suppl 2):S80–9.
11. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: 
a review of the available evidence. Clin Infect Dis 2009; 49:561–73.
12. Dimova RB, Zeremski M, Jacobson IM, et al. Determinants of hepatitis C virus 
treatment completion and efficacy in drug users assessed by meta-analysis. Clin 
Infect Dis 2013; 56:806–16.
13. Grebely J, Puoti M, Wedemeyer H, et al. Safety and efficacy of ombitasvir, pari-
taprevir/ritonavir and dasabuvir with or without ribavirin in chronic hepatitis C 
patients receiving opioid substitution therapy: a pooled analysis across 12 clinical 
trials. J Hepatol 2017; 66:S514.
14. Grebely J, Jacobson IM, Kayali Z, et al. SOF/VEL/VOX for 8 or 12 weeks is well 
tolerated and results in high SVR12 rates in patients receiving opioid substitution 
therapy. J Hepatol 2017; 66:S513.
15. Christensen S, Schober A, Mauss S, et  al. DAA-treatment of HCV-infected 
patients on opioid substitution therapy (OST): does the clinical setting mat-
ter? Data from the German Hepatitis C-Registry (DHC-R). Hepatology 2016; 
64(S1):982A–3A.
16. Schìtz A, Moser S, Marchart K, et al. Direct observed therapy of chronic hepatitis 
C with interferon-free all-oral regimens at a low-threshold drug treatment facili-
ty-a new concept for treatment of patients with borderline compliance receiving 
opioid substitution therapy. Am J Gastroenterol 2016; 111:903–5.
17. Scherz N, Brunner N, Bruggmann P. Direct-acting antivirals for hepatitis C in 
patient in opioid substitution treatment and heroin assisted treatment: real-life 
data. J Hepatol 2017; 66:S726.
18. Dillon J, Mauss S, Nalpas C, et  al. Efficacyand safety of Simeprevir-containing 
hepatitis C therapy in patients on opiate substitution therapy. J Hepatol 2017; 
66:S520.
19. Boyle A, Marra F, Fox R, et al. Partial directly observed therapy with ombitasvir/
paritaprevir based regimens allows for successful treatment of patients on daily 
supervised methadone. J Hepatol 2017; 66(1):S282.
20. Dore GJ, Altice F, Litwin AH, et al; C-EDGE CO-STAR Study Group. Elbasvir-
grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist 
therapy: a randomized trial. Ann Intern Med 2016; 165:625–34.
21. Grebely J, Mauss S, Brown A, et al. Efficacy and safety of ledipasvir/sofosbuvir 
with and without ribavirin in patients with chronic HCV genotype 1 infection 
receiving opioid substitution therapy: analysis of phase 3 ION trials. Clin Infect 
Dis 2016; 63:1405–11.
22. Grebely J, Dore GJ, Zeuzem S, et al. Efficacy and safety of sofosbuvir/velpatasvir 
in patients with chronic hepatitis C virus infection receiving opioid substitution 
therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis 2016; 63:1479–81.
23. Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir/paritaprevir/r and dasabuvir 
plus ribavirin in HCV genotype 1-infected patients on methadone or buprenor-
phine. J Hepatol 2015; 63:364–9.
24. Afdhal N, Zeuzem S, Kwo P, et al; ION-1 Investigators. Ledipasvir and sofosbuvir 
for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889–98.
25. Afdhal N, Reddy KR, Nelson DR, et  al; ION-2 Investigators. Ledipasvir and 
sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 
370:1483–93.
26. Kowdley KV, Gordon SC, Reddy KR, et al; ION-3 Investigators. Ledipasvir and 
sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 
2014; 370:1879–88.
27. Feld JJ, Jacobson IM, Hézode C, et al; ASTRAL-1 Investigators. Sofosbuvir and 
velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 
373:2599–607.
28. Foster GR, Afdhal N, Roberts SK, et  al; ASTRAL-2 Investigators; ASTRAL-3 
Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N 
Engl J Med 2015; 373:2608–17.
29. Jacobson IM, Lawitz E, Gane EJ, et  al. Efficacy of 8 weeks of sofosbuvir, vel-
patasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 ran-
domized trials. Gastroenterology 2017; 153:113–22.
30. Bourlière M, Gordon SC, Flamm SL, et  al; POLARIS-1 and POLARIS-4 
Investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV 
infection. N Engl J Med 2017; 376:2134–46.
31. Grebely J, Matthews GV, Hellard M, et al; ATAHC Study Group. Adherence to 
treatment for recently acquired hepatitis C virus (HCV) infection among inject-
ing drug users. J Hepatol 2011; 55:76–85.
32. Grebely J, Dalgard O, Cunningham EB, et al. Efficacy of response-guided directly 
observed pegylated interferon and self-administered ribavirin for people who 
inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. 
Int J Drug Policy. 2017; 47:177–186.
33. Grebely J, Alavi M, Micallef M, et al; ETHOS Study Group. Treatment for hepatitis C 
virus infection among people who inject drugs attending opioid substitution treat-
ment and community health clinics: the ETHOS study. Addiction 2016; 111:311–9.
34. Alavi M, Grebely J, Micallef M, et  al; Enhancing Treatment for Hepatitis C in 
Opioid Substitution Settings (ETHOS) Study Group. Assessment and treatment 
of hepatitis C virus infection among people who inject drugs in the opioid substi-
tution setting: ETHOS study. Clin Infect Dis 2013; 57(Suppl 2):S62–9.
35. Treloar C, Rance J, Grebely J, Dore GJ. Client and staff experiences of a co-located 
service for hepatitis C care in opioid substitution treatment settings in New South 
Wales, Australia. Drug Alcohol Depend 2013; 133:529–34.
36. Simmons B, Saleem J, Hill A, et al. Risk of late relapse or reinfection with hepatitis 
C virus after achieving a sustained virological response: a systematic review and 
meta-analysis. Clin Infect Dis 2016; 62:683–94.
37. Cunningham EB, Applegate TL, Lloyd AR, et al. Mixed HCV infection and rein-
fection in people who inject drugs–impact on therapy. Nat Rev Gastroenterol 
Hepatol 2015; 12:218–30.
38. Midgard H, Bjøro B, Mæland A, et al. Hepatitis C reinfection after sustained viro-
logical response. J Hepatol 2016; 64:1020–6.
